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Abstract
The enumeration of the interaction partners of the cellular prion protein, PrP
C, may help clarifying its elusive molecular
function. Here we added a carboxy proximal myc epitope tag to PrP
C. When expressed in transgenic mice, PrPmyc carried a
GPI anchor, was targeted to lipid rafts, and was glycosylated similarly to PrP
C. PrPmyc antagonized the toxicity of truncated
PrP, restored prion infectibility of PrP
C-deficient mice, and was physically incorporated into PrP
Sc aggregates, indicating that
it possessed all functional characteristics of genuine PrP
C. We then immunopurified myc epitope-containing protein
complexes from PrPmyc transgenic mouse brains. Gentle differential elution with epitope-mimetic decapeptides, or a
scrambled version thereof, yielded 96 specifically released proteins. Quantitative mass spectrometry with isotope-coded
tags identified seven proteins which co-eluted equimolarly with PrP
C and may represent component of a multiprotein
complex. Selected PrP
C interactors were validated using independent methods. Several of these proteins appear to exert
functions in axomyelinic maintenance.
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Introduction
The cellular prion protein, PrP
C, is required for susceptibility to
prion infections [1,2], for prion toxicity [3], and for prion
transport within the body [4]. PrP
C is a conserved glycoprotein
that is anchored to the cell surface through a covalently attached
glycosyl phosphatidyl inositol (GPI) residue [5]. PrP
C undergoes a
complex biogenesis encompassing co-translational secretion into
the lumen of the endoplasmic reticulum, cleavage of an N-
terminal signal peptide, addition of complex N-linked carbohy-
drate chains at two sites [6], addition of a preformed GPI anchor
at its very C-terminus (Ser
230), and removal of a C-terminal
oligopeptide.
Despite the detailed chemical knowledge described above, the
molecular details of the process by which PrP
C is converted into a
disease-associated homologue, PrP
Sc, are unclear [7]. Likewise, the
chain of events emanating from prion infections and leading to
neurodegenerative changes and clinical signs is unknown. Lastly,
the physiological function of PrP
C is unclear [8]. Most of the above
processes may require interactions with proteins other than PrP,
yet the nature of such interaction partners is largely unknown. The
present study was initiated as an approach to discovering the
functionally relevant interaction partners of PrP
C.
Several diverse approaches have been used in the past to
achieve the latter goals. In some instances, however, the
techniques employed were not sufficiently sensitive or were
fraught with other problems. Classical two-hybrid screens, in
which fusion proteins leads to biological readouts in the cytosol of
yeast, tend to produce when applied to membrane proteins like
PrP
c. The same holds true for cross-linking experiments, in which
proteins resident in the same micro-environment may become
linked together even if they do not functionally interact with each
others.
In order to avoid the problems described above, and to
minimize any interference with the conditions existing in vivo, we
isolated native protein complexes containing PrP
C and character-
ized them by mass spectrometry. The addition of epitope tags, for
which high-affinity antibodies are available, has proven instru-
mental for the study of many supramolecular complexes. The
engineering of appropriate tags into the proteins of choice yields
‘‘molecular handles’’ through which multi-component complexes
can be immunoprecipitated and highly purified. PrP
C lends itself
to this approach as a particularly attractive bait, as its high-
resolution structure is known [9] and thereby allows for the
rational design of tags. If the precipitating antibodies are directed
against linear, non-conformational epitopes within the tag,
epitope-mimetic peptides can release the protein complexes in a
highly specific way under non-denaturing conditions. The
introduction of a tag is also a promising starting point for
identifying functionally relevant complexes since it preserves
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4446protein interactions that occur in the same region of an anti-PrP
antibody.
GFP-PrP
C fusion proteins have proved useful for determining
the subcellular distribution and trafficking of normal and mutated
prion protein [10,11,12]. However, the suitability of GFP to the
proteomic approach delineated above is limited. GFP is a bulky,
highly structured and rigid tag whose molecular weight exceeds
that of PrP
C. Therefore we reasoned that GFP may distort the
composition of any native multiprotein complex that encompasses
PrP
C.
In the present study, we have tagged the C-terminus of mouse
PrP
C with the human ‘‘myc-tag’’. The resulting chimaeric protein,
termed PrPmyc, was used to immunoprecipitate and characterize
the supramolecular complex containing the prion protein from
transgenic mice. Using immunoprecipitation and mass spectrom-
etry, we have identified a set of proteins associated with PrPmyc.
Since the conversion of cellular prion protein PrP
C into the
proteinase K-resistant isoform PrP
Sc is the central pathogenic
process in prion diseases, we investigated whether PrPmyc can be
converted into PrP
Sc. Our results indicate that C-terminally myc-
tagged prions can contribute to prion infectivity and to
neurotoxicity. Therefore, myc tagged PrP
Sc may also allow for
identification of proteins interacting with PrP
Sc.
Results
Transgenic mice expressing C-terminally tagged PrP
We tagged the murine prion protein by introducing a human
myc epitope tag (EQKLISEEDL) at its C terminus next to Ser
230
and amino proximally to the C-terminal signal sequence for the
GPI anchor (Fig. 1A). As the minimal myc epitope tag consists of
only 10 amino acids, we reasoned that it might not interfere with
the geometry and proper folding of PrP
C, and with its function.
The human myc epitope tag was detectable by both monoclonal
anti-myc antibodies 9E10 and 4A6 [13]. To guarantee correct
GPI linkage of this fusion protein, the sequence comprising Ser
230
and its four immediately preceding N-proximal amino acids was
duplicated after the tag. The resulting fusion molecule was termed
PrPmyc.
Preliminary analyses of PrPmyc transfected cells indicate that the
biosynthesis, processing, and trafficking of the resulting fusion
protein were indistinguishable from those of endogenous PrP
C
(data not shown).
To generate transgenic mice expressing C-terminally tagged
PrP, PrPmyc was ligated into the ‘half-genomic’ phgPrP backbone,
driven by the endogenous Prnp promoter [14]. Pronuclear
injections of linearized purified DNA were performed into
fertilized oocytes derived from a B6D2F16B6;129S5-Prnp
o/o
mating. Four founder mice were identified by PCR analysis using
primers TAP 20 (59- CCG ATG TGA AGA TGA TGG AGC)
and myc 22 (59- CCG TCG ATC GGA TTC AGA TCC) specific
for the myc-tag amplicon. The two highest-expressing lines,
termed Tg(PrPmyc)940Zbz and Tg(PrPmyc)941Zbz (henceforth
Tg940 and Tg941 for brevity) were chosen for further propagation.
Southern blot analysis revealed that Tg940 and Tg941 mice
harbored 6 copies and 1 copy of the transgene per haploid
genome, respectively (Fig. 1B). Northern blot analysis performed
on total RNA from brains of PrPmyc mice confirmed transcription
of transgenic PrPmyc (Fig. 1C). Transgenic mice expressing PrPmyc
did not show any anatomical or behavioral abnormalities, survived
in health for .700 days, and did not show any neurohistological
changes. We monitored weight and food uptake until adolescence.
Transgenic mice had shiny fur indicative of good general health,
and reproduced with frequency and litter sizes comparable to
wild-type mice (data not shown). We did not recognize any
difference in locomotor activity from wild-type mice over a period
of .2 years.
To obtain transgenic strains that only expressed PrPmyc yet no
endogenous PrP, both transgenic founders Tg940 and Tg941 were
crossed twice to Prnp
o/o mice. Transgene expression in brain and
spleen of these mice was analyzed by Western blotting using anti-
PrP antibody POM1 [15], and mouse monoclonal anti-myc
antibody 9E10. Tg940 mice lacking PrP
C (henceforth termed
Tg940 PrPo=o
myc) expressed 1.6 fold more of PrPmyc protein in brain
than wild-type mice (Fig. 1D), but had lower expression levels of
the transgene in spleen (about 0.5 fold of Prnp
+/o mice, data not
shown). Expression of PrPmyc in Tg941 PrPo=o
myc was approximately
0.33 fold in brain and 2-fold in spleen of PrP
C expression in Prnp
+/o
mice (data not shown). Tg940 and Tg941 exhibited a three-banded
pattern very similar to PrP
C glycoforms (37–25 kDa) in wild type
mice (Fig. 1E).
PrPmyc is localized within detergent resistant membranes
(DRMs)
We isolated DRMs from Tg940 brain tissue by gradient
centrifugation [16]. A series of fifteen individual fractions was
carefully removed from the tubes after centrifugation of typical
DRM preparations from mouse cerebella of Tg940 PrPo=o
myc, and
analyzed by Western blotting. The quality of the preparations was
monitored using the control proteins flotillin 2 is known to reside
in DRMs [17,18]. PrPmyc was found to reside in the same fractions
as these proteins, confirming its localization in these specialized
membrane domains (Fig. 1F). Therefore, the subcellular localiza-
tion of PrPmyc was similar to that of endogenous PrP
C.
Testing the functionality of PrPmyc
Tg940 PrPo=o
myc were crossed with the TgF35 line of mice
expressing N-proximally truncated PrP, henceforth referred to as
PrPDF. PrPDF mice suffer from degeneration of the cerebellar
granular layer, leukoencephalopathy, and death at about 100 days
of age [19,20,21]. This phenotype is dose-dependently counter-
acted by endogenous or transgenic co-expression of wild-type
PrP
C, presumably because of a competing activity supplied by
PrP
C.
If the tagged protein PrPmyc is functional and appropriately
localized, it should also rescue PrPDF mice from neurodegenera-
tion. Indeed, Tg940 PrPo=o
myc expressing PrPDF survived for
551673 days (n=5; Fig. 1G) and maintained a normal weight
throughout their lifetime. Mice were examined twice per week for
neurological symptoms and scored as described [19], yet did not
show clinical signs of CNS disease at any time. Furthermore, they
did not develop histopathological changes in brain or other organs
(data not shown), suggesting that PrPmyc is functional in vivo. Age
and sex-matched PrPDF siblings died between 12 and 14 weeks of
age (mean survival: 9567 days, n=5; Fig. 1G).
In contrast, double-transgenic mice of the lower expressing line
(Tg941) were not completely rescued and began to show first signs
of illness around day 280. Some animals had to be sacrificed at the
age of 12 months due to hind leg paresis (mean survival
391657 days, n=9; Fig. 1G). As Tg941 PrPo=o
myc mice express
about one-third of the PrPmyc found in brains of Tg940 PrPo=o
myc
mice, this indicates that the action of PrPmyc, like that of PrP
C,i s
dose-dependent.
Neuropathology in inoculated PrPz=o
myc mice
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prions (RML strain, passage 5). After low dose intraperitoneal (ip)
inoculation with 10
3 IU or intracerebral (ic) inoculation with 300
IU of RML5 brain homogenate, Tg940 PrPz=o
myc mice showed signs
of CNS dysfunction at 250692 (n=5/5) and 236676 (n=6/6)
days post inoculation (dpi), respectively (Fig. 2A and B). Mice
expressing less PrPmyc in brain (Tg941) developed signs of CNS
dysfunction and terminal scrapie disease more slowly, at 316620
(n=4/4) days after low-dose intracerebral inoculation (Fig. 2B and
Table S1).
Brain homogenates prepared from terminally sick Tg940
PrPz=o
myc mice were inoculated ic into tga20 mice overexpressing
PrP
C [14] to test for infectivity in an in-vivo mouse assay. All of the
tga20 mice developed neurological signs of terminal scrapie at
around 80 dpi (Table S1). Prion infection was confirmed by
immunochemical and histopathological analysis in all terminally
sick mice. PrPz=o
myc mice developed neurological dysfunction and
terminal disease significantly earlier than Prnp
+/o mice: the mean
incubation time was 27669 days for Prnp
+/o (n=6) and
226613 days for Tg940 PrPz=o
myc mice (n=8) after high dose ic
inoculation (Fig. 2C and Table S1). Therefore, PrPmyc contributes
to, rather than interfering with, prion pathogenesis in Prnp
+/o
mice.
In all terminally sick PrPz=o
myc mice tested we detected proteinase
K (PK) resistant material in brain and spleen after ic or ip
inoculation with RML prions. To distinguish between wild-type
PrP
Sc and PrPSc
myc we stained Western blots of brain homogenates
with an anti-myc antibody (Fig. 2D). PK-resistant PrPSc
myc was
clearly detectable under these conditions, indicating that PrPmyc
itself is convertible, and suggesting that this phenomenon
contributed to the shortened incubation periods in PrPz=o
myc mice.
Comparison of immunohistochemically stained brain sections of
terminal Prnp
+/o and Tg940 PrPz=o
myc mice did not reveal any
striking differences in the extent and topography of reactive
astrocytic gliosis, vacuolar degeneration and PrP aggregates
(Fig. 2E–K).
Neuropathology in inoculated PrPo=o
myc mice
To investigate whether PrPmyc can be converted into myc-
tagged PK-resistant PrPSc
myc even in the absence of a wild-type PrP
allele, we inoculated PrPo=o
myc mice with RML prions. No PrP
Sc was
detected in brain and spleen at 50 to 100 days after ic or ip
inoculation, yet 8 of 34 (23%) PrPo=o
myc mice eventually developed a
progressive neurological syndrome clinically indistinguishable
from scrapie after RML inoculation (Table S2). Brain homogenate
from these sick mice was then used to inoculate a second
generation of Tg940 PrPo=o
myc mice. Western blot analysis of brain
homogenate from these second-passage ic-inoculated Tg940
PrPo=o
myc mice revealed PK-resistant PrP; these mice had clinical
signs of scrapie and developed vacuolation in the neuropil, intense
astrogliosis, and abundant PrP aggregates (Fig. 3A–C). For
control, Tg940 PrPo=o
myc mice were inoculated with non-infectious
brain homogenate. These mice showed no evidence of vacuolar
degeneration or nerve cell loss, and only mild astrogliosis when
aged (Fig. 3D–F).
As an additional method to distinguish between PrP
Sc derived
from wild-type PrP and PrPmyc we performed histoblot analysis of
cryosections of terminal Tg940 PrPo=o
myc mice and Tg940 PrPz=o
myc
mice (Fig. 3G–I). Using anti-PrP (POM1) and anti-myc (4A6)
antibodies, we could specifically detect PK-resistant PrP in
terminal C57BL/6 mice, Tg940 PrPo=o
myc and Tg940 PrPz=o
myc mice.
This technique allowed us to map the distribution of PrP
Sc in
different transgenic mice.
We then investigated whether PrPmyc infectivity would increase
upon serial transmission, as frequently observed in strain
adaptation [22]. Brain homogenate derived from RML-inoculated
Tg940 PrPz=o
myc mice was passaged into Tg940 PrPo=o
myc mice which
all got sick after 590656 days (n=3) (Table S3). One of these
second-passage mice was used as a source for a third passage into 5
Tg940 PrPo=o
myc mice. All of them show similar neurological signs as
in the second passage, but with a shorter incubation period of
367638 (n=5), which is suggestive of strain adaptation (Table S3).
We then tested whether deposition of PrP
Sc accompanies prion
replication, defined as increase in prion infectivity. Samples from
Tg940 PrPo=o
myc mice after the second passage were used to infect
the PK1 subclone of N2a neuroblastoma cells in the Scrapie cell
assay in endpoint format (SCEPA [23]). As shown in the Fig. 3 J
the titer for the PrPSc
myc is the same as the standard RML.
Identification of PrPmyc -containing protein complexes
Crude brain homogenates from Tg940 PrPo=o
myc mice were
subjected to immunoprecipitation (IP) experiments with paramag-
netic microbeads coupled to mouse monoclonal anti-myc antibody
(4A6, Upstate, USA). Release of myc-containing protein com-
plexes from beads was carried out by exposing the beads to an
excess of the synthetic epitope-mimicking myc peptide described
above. Control experiments were carried out to verify the
specificity of the eluted proteins, and included (1) incubation of
beads with 129S2/SvPas wild-type brains followed by elution with
the myc peptide, as well as (2) incubation of beads with Tg940
PrPo=o
myc homogenate followed by elution with a scrambled version
of the myc peptide. In the eluates from 4A6-coupled beads
Figure 1. Molecular characterization of the PrPmyc transgenic mouse lines Tg940 and Tg941. (A) Scheme of the PrPmyc transgene. SP:
secretory signal peptide, cleaved after sorting of the precursor to endoplasmic reticulum; repeats: five repeats of eight amino acids; CC: charge
cluster; HC: hydrophobic core; H1, H2, H3: a-helices of the globular carboxy-proximal domain; MYC: human myc epitope tag (EQKLISEEDL); MA:
membrane anchor of precursor protein, replaced during maturation with glycosyl phosphatidyl inositol anchor. (B) Southern blot analysis of lines
Tg940 PrPmyc (lanes 1, 2, 6) and Tg941 PrPmyc (lanes 3, 5, 7). Lane 4: Tg941 PrPo=o
myc mouse co-expressing N-proximally truncated PrPDF. Lane 8: PrPDF
mouse. The bands diagnostic for PrPmyc and PrPDF were 3039 and 2709 bp, respectively. Numbers of transgenic copies per haploid genome, as
determined by quantitation of Southern blot signals against the respective Prnp
o genomic band, revealed higher copy numbers in Tg940 PrPmyc (#6)
than in Tg941 PrPmyc mice (#1). (C) Northern blot analysis of individual Tg940 PrPmyc and Tg941 PrPmyc brains using a Prnp probe. Mice homozygous
for the transgenic allele PrPmyc (lanes 2, 3, 4 from Tg940 and lanes 8, 11 from Tg941) showed higher levels of PrPmyc mRNA than hemizygous mice
(lanes 1 and 5 from Tg940 and lanes 6, 9, 10 from Tg941). An actin probe was used as a loading control (lower panel). (D) Similar expression levels of
transgenic protein from Tg940 PrPo=o
myc, and full-length PrP from 129S2/SvPas wild-type mice, analyzed by Western blotting of total brain homogenate
using anti-PrP antibody POM1. (E) Similar glycosylation pattern of full-length PrP from 129S2/SvPas wild-type and PrPmyc from Tg940 PrPo=o
myc mice.
Brain homogenates were subjected to PNGase F treatment as indicated, and analyzed by Western blotting using POM1 antibody to PrP
C.( F)
Detergent-resistant membrane preparations from cerebella of Tg940 PrPmyc transgenic mice showed PrPmyc in lipid rafts. PrPmyc was detectable by
Western blotting in fractions with 5–30% Optiprep. PrPmyc resided in the same fractions as flotillin (48 kDa) confirming its localization in DRMs. (G)A
genetic in vivo assay for the function of the PrPmyc protein. Survival curves of mice expressing PrPDF in absence of full length PrP
C and in presence of
PrPmyc from two transgenic lines. Toxicity of PrPDF was counteracted by PrPmyc, leading to a longer survival and suggesting that PrPmyc has retained at
least some of the function of PrP
C. Line PrPDF, Tg940 and Tg941 consisted of 5, 5, and 9 individuals, respectively.
doi:10.1371/journal.pone.0004446.g001
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myc mice after prion inoculation. (A) Survival curves of Tg940 PrPz=o
myc mice and Prnp
+/o mice
low dose ip inoculated with RML5 prions. Groups Tg940 PrPz=o
myc ip Prnp
+/o ip consisted of 5 and 2 individuals, respectively. (B) Survival curves of
Tg940 PrPz=o
myc , Tg941 PrPz=o
myc , and Prnp
+/o mice inoculated low dose ic with RML5 prions. Group Tg940 PrPz=o
myc comprises 6, group Tg941 PrPz=o
myc 4,
and Prnp
+/o 3 individuals, respectively. (C) Survival curves of Tg940 PrPz=o
myc mice and Prnp
+/o mice high dose ic inoculated with RML5 prions. Line
Tg940 PrPz=o
myc comprises of 8 and line Prnp
+/o of 6 individuals, respectively. (D) PrPmyc was converted into myc-tagged proteinase K-resistant PrPSc
myc
in presence of a wild-type PrP allele. Western blot analysis using brain homogenate from an inoculated, terminally sick PrPz=o
myc mouse. Antibodies
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C
was not detected, whereas only traces of PrP
C were detected in the
scrambled-peptide eluate from IPs of Tg940 PrPo=o
myc brain
homogenates (Fig. 4A).
Inspection of silver-stained gels revealed more protein bands in
the specific than in the unspecific elution fraction (Fig. 4B), in
particular the PrPmyc band exclusively present in the myc-specific
eluates from Tg940 PrPo=o
myc brain homogenates. The correspond-
ing lanes were cut into slices, proteins were extracted, and tryptic
peptides were identified by liquid chromatography followed by
tandem mass spectrometry (LC-MS/MS). As a further quality
control, we verified that the identified proteins originated from the
gel area corresponding to their predicted molecular size. Table S4
lists those proteins that were coprecipitated with PrPmyc from
transgenic brains, yet were not detected in material immunopre-
cipitated from wild-type brains and unspecific elution under the
same conditions. While 442 individual proteins were detected in
both the specific and the nonspecific eluates, and 277 proteins
were uniquely present in the nonspecific eluate, 96 proteins were
present in the specific eluate but absent from the nonspecific
eluate.
We then sought to determine the relative abundance of PrP and
the interacting proteins in the specific and unspecific peptide
elution fractions by using cleavable isotope-coded affinity tags
(cICAT) as a quantitative mass spectrometric technique. In the
classical cICAT approach the two labeled fractions contain the
same amount of protein. Since this is not the case for the specific
and unspecific IP elution fractions, we could only determine the
relative ratio of PrP between the specific and the unspecific elution
fractions.
The two elution fractions derived from immunoprecipitations of
PrPmyc and wild-type brains were labeled with the ‘‘heavy’’
(cICAT-13C9) and ‘‘light’’ (cICAT-12C9) cICAT tags, mixed, and
mass/charge (m/z) elution profiles were determined by mass
spectrometry. Sequest [24], PeptideProphet [25] and XPRESS
were used to identify the proteins and to access the cICAT ratios
(Fig. 4C, Table S5). Of the 157 peptide pairs that could be
assigned to a heavy/light ratio between 0.1 and 100, seven
proteins were found to have a comparable ratio to PrP and, at the
same time, were identified as specific proteins by the gel-based
approach (Table 1). Any ratios below 1 are indicative of proteins
more abundant in the scrambled elution than in the myc-specific
elution. Proteins displaying a similar abundance in both samples
would yield a ratio of 1, which most probably indicates nonspecific
binding to and elution from the beads. The ratio for PrP was about
14, and the proteins listed in Table 1 represent values between 4
and 15.
We then sought to confirm the results of mass spectrometric
analyses by immunochemical analyses of selected proteins. Indeed,
the identity of PrP, 29,39-cyclic nucleotide 39-phophodiesterase,
M6-a and Neurofascin was unambiguously confirmed by Western
blot analysis. Fig. 4D shows the characteristic double band of
CNPase after myc-peptide elution and a low-intensity band for the
scrambled-peptide elution. Western blot analysis with antibodies
to Neurofascin 155 and M6a revealed specific bands for the
specific-peptide elution but in none of the negative controls
(Fig. 4E–F). The signal for M6a from the specific elution shows
two strong bands most probably originating from alternative
splicing. For both Neurofascin and M6a, the protein expression
level in wt and Tg940 PrPo=o
myc brain were approximately the same
as illustrated in Fig. 4E–F.
Discussion
Our understanding of the function of PrP
C and its conversion
into PrP
Sc continues to be sketchy. Genetic experiments have
helped defining the domains of PrP
C necessary for prion
propagation [21] and, with some limitations, for PrP
C function
[19,26,27,28], yet have failed to identify any further proteins that
may be required for this process. However, progress in this field
may crucially benefit from enumerating and/or manipulating the
PrP-interacting proteome. Towards the latter goals, we have
studied the biogenesis, localization in vitro and in vivo of a C-
terminally myc-tagged version of PrP
C (PrPmyc). Since the
physiological function of PrP
C is unknown, we used a well-
established approach of reverse genetics [14] to assay the
biological activity of PrPmyc. This approach is so far the most
proximal surrogate to study the function of PrP. We found PrPmyc
to be fully functional and substitute dosage-dependently for
endogenous PrP in rescuing the neurodegenerative phenotype
induced by PrPDF.
Conversion of cellular prion protein PrP
C into the disease-
causing isoform PrP
Sc is the central pathogenic process in prion
diseases [29]. Therefore, any claim of the biological authenticity of
a modified PrP protein should be substantiated by its ability to
sustain prion replication. We approached this important question
in a variety of paradigms. Whereas direct intracerebral inoculation
of PrPo=o
myc transgenic mice with prions rarely induced scrapie, we
found that in the presence of a wild-type Prnp allele PrPmyc is
converted into a PK-resistant isoform (PrPSc
myc). The disease of
prion-infected PrPz=o
myc mice was transmissible by ic inoculation of
brain homogenates to wild-type mice and also, importantly, to
PrPo=o
myc mice. Since it is known, that PrP
Sc levels do not necessarily
correlate with infectivity titers, we decide to evaluate the infectivity
titers by SCEPA and compare to RML, and also in that paradigm
PrPmyc behave as normal RML. The latter finding establishes
beyond any doubt that PrPmyc supports prion replication and
scrapie pathogenesis.
In many paradigms, expression of heterologous PrP molecules
which differ from the endogenous PrP by as little as one amino
acid can profoundly interfere with the overall accumulation of
PrP
Sc [30,31], suggesting that precise homotypic interactions
between PrP molecules are important for PrP
Sc accumulation
[31,32]. However, when inoculated with the same dose of prions,
PrPz=o
myc mice developed disease faster than Prnp
+/o mice, implying
that PrPmyc cooperates, rather than interfering, with PrP
C in
disease pathogenesis. This was unexpected in view of the many
instances of interference that have documented to occur even
between naturally occurring PrP alleles [12]. If one accepts that
interference is brought about by disturbances of the replicative
interface of prions, one might speculate that the carboxy terminus
of PrP
C does not participate to such an interface.
POM1 to PrP and 4A6 to myc were used for detection. Samples were treated with PK as indicated, revealing the presence of protease resistant PrPmyc
in the brain of inoculated Tg940 PrPz=o
myc mice. (E–G) Similar neuropathological changes in hippocampus of a RML inoculated Prnp
+/o mouse and (H–
K) a RML-inoculated Tg940 PrPz=o
myc mouse. (E, H) Hematoxylin-eosin stains showing vacuolar degeneration and nerve cell loss. The dashed lines
indicate the magnified area shown in F,G,J and K. Scale bar=500 mm. (F, J) GFAP immunohistochemistry for the detection of reactive astrocytes and
(G, K) mAb SAF84 for PrP aggregates. Scale bar=200 mm. The small inserts represent the low magnification pictures of the GFAP and SAF84 stained
sections consecutive to E and H. Scale bar=500 mm.
doi:10.1371/journal.pone.0004446.g002
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PLoS ONE | www.plosone.org 7 February 2009 | Volume 4 | Issue 2 | e4446The latter conclusion, however, is tempered by another
observation. When PrPo=o
myc mice were inoculated with RML
prions, only few animals developed clinical signs of scrapie. This
suggests that the C-terminally modified prion protein presents a
‘‘prion transmission barrier’’ to mouse-adapted sheep prions,
analogously to the species barriers seen in many natural and
experimental prion diseases [33]. The similarities between the
amino acid sequence of donor PrP
Sc and recipient PrP
C play a
crucial role in the species barrier [34,35], but the structural
understanding of these constraints is still very sketchy. In the
PrPmyc transgenic model, the species barrier exists if wild-type
prions are transmitted into PrPo=o
myc animals, but can be overcome if
brain homogenates from terminally sick PrPz=o
myc mice containing
PrPSc
myc is passaged into PrPo=o
myc transgenic mice.
The successful production of myc-tagged, self-propagating and
disease-causing prions paves the way to many studies in vitro and in
vivo by taking advantage of the high-affinity reagents available to
the myc epitope. For example, the myc-tagged prion inoculum
may allow for investigating the fate of inoculated prions in vivo,
since PrPmyc can be detected and traced by tag-specific antibodies
which do not recognize endogenous PrP. In the present study, we
provide evidence that PrPmyc is useful for probing the PrP
C-
associated proteome. We have established a novel method for the
specific elution of multiprotein complexes containing PrPmyc.W e
have exploited this method for identifying several candidate
proteins which appear to interact with PrP
C in vivo. The specificity
of these interactions was validated by comparison to wild-type
brain eluates and elution with a scrambled peptide. Some of the
PrP-interacting proteins describe before and summarized in recent
reviews [36,37], including for instance Tubulin, Hsp60 and
Laminin, were detected in the specific as well as unspecific elution
fraction of our approach and therefore not included into the list of
possible candidates.
We utilized a quantitative MS technique, isotope-coded affinity
tagging (ICAT), to determine the relative abundance of PrP and
other proteins in the various samples, so to identify proteins that
might exist in an equimolar complex with PrP
C. Such PrPmyc-
interacting proteins would display an ICAT ratio of specific/
unspecific signals similar to that of PrP
C. Based on this mass
spectrometric approach, we found a small number of protein
candidates equimolarly associated with PrPmyc in native brain
homogenates.
There are some caveats to the equimolarity filter described
above. Supramolecular complexes encompassing PrP
C may
contain superstoichiometric amounts of accompanying molecules,
in which case the ICAT ratios may be skewed. Conversely, if PrP
C
exists in a free form as well as in a complex, or in several different
complexes, the partner proteins may appear to be substoichio-
metric in an immunoprecipitate. Therefore, even if the seven
proteins identified here represent promising candidates, the
remaining hits detailed in Table S4 should not be dismissed
because of their non-equimolar ICAT ratios.
Two of the latter seven proteins (Q80U89 clathrin linked;
Q01853 translational ER ATPase) are not well-characterized and
no antibodies to them appear to be available. Chondroitin sulfate
proteoglycan core protein was described to strongly inhibit neurite
outgrowth of central and peripheral neurons [38]. It was also
reported that neurite outgrowth is modulated – at least in culture
models – by interactions between PrP
C, NCAM and STI-1, which
can lead to activation of intracellular signalling pathway [39].
Several PrPmyc interactors belong to the families of neuronal
glycoproteins and myelin-associated proteins. These include the
neuronal membrane glycoprotein M6-a, Neurofascin, and 29,39-
cyclic nucleotide 39-phophodiesterase (CNP). P0 glycoprotein of
compact PNS myelin, myelin-associated glycoprotein (MAG), and
others have well-defined roles in the formation, maintenance and
degeneration of myelin sheaths [40]. Myelin proteins also appear
to mediate signals between the myelin-forming cell and the axon
[41]. Current research suggests that CNP is required for
maintenance of axon-glial interactions at the nodes of Ranvier
in the CNS [42]. The interaction between PrP and CNP may
underlie the myelin damage observed in old Prnp
o/o mice [43] and
in various transgenic PrP deletion mutants age [19,20,21]. In
support of this hypothesis, recent studies suggest that myelin
integrity may be maintained by a constitutively active neuro-
trophic protein complex involving PrP
C [19].
A possible functional relation between neurofascin and PrP
C is
particularly intriguing in view of the lethal phenotype of transgenic
mice expressing PrP deletion mutants, which display extensive
central and peripheral myelin degeneration [19]. Neurofascin 186
(NF186) is expressed prenatally on dorsal root ganglia neurons and
it may modulate their adhesive interactions with Schwann cells,
which express NF155 postnatally and require it for development of
axon–glial paranodal junctions. The major isoform of NF186
inhibits cell adhesion, and this activity may be important in
formation of the node of Ranvier [44].
Another enticing candidate for functionally relevant interactions
is M6-a, a membrane glycoprotein involved in neuronal
differentiation as part of a Ca
2+ channel [45]. The lack of the
cellular prion protein was shown to affect Ca
2+ homeostasis in
neurons [46], and therefore it is thinkable that PrP
C and M6-a are
involved in a complex possessing an ion channel-like function.
In addition to identifying the interactors described above, the
tools introduced here may allow for studying supramolecular
complexes containing the disease-associated prion protein PrP
Sc.
The biophysical properties and aggregational state of PrP
Sc are
vastly different from those of PrP
C, and there is reason to
hypothesize that the PrP
Sc interactome will only partially overlap
with that of PrP
C. Since most prion strains are both neurotropic
and lymphotropic [47,48], and inflammatory conditions specify
Figure 3. Neuropathology of Tg940 PrPo=o
myc mice after prion inoculation. (A–C) Extensive astrogliosis and PrP aggregation in hippocampus of
an RML inoculated Tg940 PrPo=o
myc mouse compared to (D–F) Mock inoculated Tg940 PrPo=o
myc mouse: (A, D) Hematoxylin-eosin stains visualizing
vacuolar degeneration and nerve cell loss, (B, E) GFAP immunohistochemistry indicating reactive astrocytic gliosis, and (C, F) mAb SAF84 showing
PrPmyc aggregates. Scale bar=500 mm. (G–I) Conversion of PrPmyc into myc-tagged PK-resistant PrPSc
myc in mice lacking both wild-type Prnp alleles.
Histoblot analysis of coronal slices from brains of mock and prion-inoculated mice blotted onto nitrocellulose membranes. (G) Mock-inoculated
C57BL/6 and Tg940 PrPo=o
myc mice. Brain homogenates were incubated with POM1 and 4A6 before or after PK treatment, and showed no PK-resistant
PrP. (H) Prion-inoculated Tg940 PrPo=o
myc and Tg940 PrPz=o
myc mice, treated with PK and incubated with POM1 and 4A6, showed PK-resistant material in
brain. (I) Prion-inoculated Prnp
+/o, Tg940 PrPz=o
myc and Tg940 PrPo=o
myc mice treated with PK and untreated were stained with 4A6 anti-myc antibody and
show protease-resistant PrPmyc in the brain. A terminally sick Prnp
+/o mouse was used to control for nonspecific 4A6 signals. (J) SCEPA of brain
homogenates of PrPo=o
myc and wild-type mouse. Three independent biological replicas of PrPSc
myc and 2 independent biological replicas for RML were
analyzed in tenfold dilution steps using 6–12 PK1-containing replica wells for each dilution. Data points indicate the number of infectious tissue
culture units per ml of brain homogenates.
doi:10.1371/journal.pone.0004446.g003
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C and PrP
Sc in
lymphoid organs will also be of interest. The inoculation of wild-
typeanimalswith myc-taggedprions mayhelp elucidatingtheinitial
events that occur during infection of an animal with prions. Finally,
the successful conversion of PrPmyc into a protease-resistant moiety
may allow for the purification of native PrP
Sc-containing complexes
using the techniques described above for PrP
C. The latter studies
may lead to the identification of the elusive chaperones involved in
prion propagation, strain barriers and strain adaptation, as well as
the crossing of prion species barriers.
Materials and Methods
Generation of myc-tagged PrP
C
PCRs were performed in 50 ml volumes containing 10 ng of
template DNA phgPrP [14], 200 mM of each dNTP, 20 pmol of
Figure 4. Isolation of PrPmyc and PrPSc
myc from Tg940 PrPo=o
myc and Tg940 PrPz=o
myc brains. (A) Western blot analysis of the material used for IP of
PrP
C. Equal amounts of brain homogenates from wild-type 129S2/SvPas and Tg940 PrPo=o
myc mice were used for immunoprecipitations. Specifically
eluted PrPmyc protein was detected with anti-PrP antibodies as well as 4A6 anti-myc antibody (data not shown). No signal for PrP in the specific
elution (s.e.) from the precipitation in 129S2/SvPas brain homogenate, and only weak signals from the elutions with unspecific peptide (u.e.), or with
PBS only (b.e.). (B) Silver stain of the material immunocaptured with anti-myc antibodies from total brain homogenate of Tg940 PrPo=o
myc and eluted
with myc and cym peptide. The gel was subsequently used for GeLC-MS/MS experiments. (C) Blot of peptide pair frequency against XPRESS-Ratios on
a logarithmic scale. Values of ratios where one of the two labeled peptide was not detected (1:0 or 0:1) were excluded from the dataset. The ratio of
the cystein-containing peptide pair of PrP heavy/light is indicated by the green circle. (D–F) Western blot analysis of those protein candidates listed in
Table 1 for which specific antibodies were available. (D) Western blot analysis of the specific and scrambled-peptide IP elution using anti-CNPase
antibody. (E–F) Western blot analyses of IP input material from wild-type 129S2/SvPas and Tg940 PrPo=o
myc mice and specific and unspecific peptide
elution using anti-M6 (M6-7) and anti-Neurofascin (NF155) antibodies.
doi:10.1371/journal.pone.0004446.g004
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TCT AGC TAT CCC AGG TGG GA-39, ClaI: 59-TTT TTT
TTA TCG ATC GAC GGC AGA AGA TCG AGC AGC ACC
GTG CTT TTC TCC TCC CCT CCT GTC ATC-39, Xma: 59-
TTT TTT TTC CCG GGC AGG GAA GCC CTG GAG GCA
ACC GTT-39, ClaI: 59-TTT TTT TTA TCG ATC TTC TCC
CGT CGT AAT AGG CCT GGG ACT C-39), 1 mlo f
’’Advantage II’’ polymerase (Clontech), 10 mlo f1 0 6 reaction
buffer supplied by the manufacturer (Clontech). Reaction mixtures
were kept at 94uC for 5 min in a thermocycler to inactivate the
blocking antibody,
,and cycled 30 times. The two PCR products of
PrP cDNA were cleaved with ClaI and ligated into the pGEM-T
easy vector system (TA cloning vector, Promega), generating
plasmid pGEM-PrP(Xma-Pml); ClaI. The final insert of pGEM-
PrP(Xma-Pml); ClaI consists of a mutated PrP cDNA fragment
extending from the XmaI restriction site of the PrP ORF to the
Pmli restriction site located 39 of the PrP coding region. The myc
tag was inserted into the unique ClaI site of pGEM-PrP(Xma-Pml);
ClaI. Two synthetic 59-phosphorylated oligonucleotides were
annealed (myc-fwd: 59-CGG AAC AAA AAC TCA TCT CAG
AAG AGG ATC TGA ATC; myc-rev: 59-CGG ATT CAG ATC
CTC TTC TGA GAT GAG TTT TTG TTC) to produce a
double-stranded DNA with 59-protruding, ClaI compatible ends
(myc-tag). The myc-fwd oligonucleotide sequence encodes the
human myc epitope, EQKLISEEDL. The myc-tag was ligated
into ClaI digested pGEM-PrP(Xma-Pml); ClaI generating pGEM-
PrP-myc(Xma-Pml); ClaI. Finally, the XmaI-PmlI fragment of
phgPrP [14] was replaced by the XmaI-PmlI fragment of pGEM-
PrP-myc(Xma-Pml); ClaI yielding plasmids phgPrP-myc and the
construct was verified by sequencing.
Generation and characterization of transgenic mice
The phgPrP-myc plasmid, driven by the endogenous Prnp
promoter in the context of the PrP ‘‘half-genomic’’ construct
(phgPrP) [14], was digested with NotI and SalI to remove its
prokaryotic backbone. Pronuclear injections were performed into
fertilized oocytes derived from a B6D2F16B6;129S5-Prnp
o/o
mating.To obtain PrPmyc transgenic animals on a Prnp
o/o knockout
background, the founders were backcrossed to homozygous
B6;129S5-Prnp
o/o mice. To differentiate PrPmyc transgenic litter-
mates with Prnp
+/o and Prnp
o/o genotype the presence of the
endogenous Prnp
+ allele was tested by PCR analysis using primers
Prnp intron 2 (59-ATA CTG GGC ACT GAT ACC TTG TTC
CTC AT) and P10rev (reverse complementary of P10 59-GCT
GGG CTT GTT CCA CTG ATT ATG GGT AC) amplifying a
352 bp product for the Prnp wild-type allele but no PCR product
for the Prnp
o allele.
For Northern blot analyses, RNA was extracted using Trizol
(Invitrogen). A randomly
32P-labeled (Rediprime II Random
Prime Labelling System, Amersham Biosciences) restriction
fragment encompassing all of exons 1 and 2, all of the ORF and
a part of exon 3 (XbaI-fragment) was used as a PrP probe. This
probe hybridizes with all wild-type and tagged PrP mRNAs as well
as the ‘‘readthrough’’ RNA from the disrupted Prnp locus [51].
Southern blot analyses were performed using a 640 bp DNA
probe synthesized by incorporation of digoxigenin-11-dUTP
(Roche, Switzerland) during PCR using PrP-specific primers and
hybridization was performed following established protocols [52].
For the actin control the Northern blot was probed with an in-
house generated mouse beta-actin probe cloned from full-length
cDNA.
Rescue of Shmerling’s disease
PrPo=o
myc mice were crossed with PrPDF [19,21] mice to obtain
double transgenic animals with Prnp
o/o genotype needed for the
experiment described in Fig. 1. Animals were examined twice each
week for symptoms of cerebellar dysfunction, including ataxia
[53], tremor, weight loss, rough hair coat, and kyphosis. Scoring of
neurological signs was performed according to a four-degree
clinical score system [19] and mice were euthanized within 3 days
of reaching a score of 3.5.
Western blot analyses
Homogenates of noninfectious brain and spleen (10% w/v) were
prepared in sterile PBS/0.5% Nonidet P-40 and protease
inhibitors (Complete; Roche, Switzerland) by repeated extrusion
through syringe needles of successively smaller size. Homogenates
of infectious brains were generated using a rhybolyzer in a
Table 1. Proteins found by GeLC-MS/MS and cICAT experiments.
UniProt accession
number Protein name and cICAT peptide sequences Gene Function/localization (ExPASy)
P16330 29,39-cyclic-nucleotide 39-phosphodiesterase,
(RPPGVLHCTTK, LDEDLAGYCRR)
Cnp Associated with membrane structures of brain white matter
Q62059 Chondroitin sulfate proteoglycan core protein 2
(Large fibroblast proteoglycan, PG-M),
(YHCKDGFIQR, YQCDEGFSQHR)
Cspg2 May play a role in intercellular signaling and in connecting cells with the
extracellular matrix. May take part in the regulation of cell motility, growth
and differentiation.
P35802 Neuronal membrane glycoprotein M6-a,
(KICTASENFLR)
Gpm6a Multi-pass membrane protein. Enriched in the granule cell layer of the
cerebellum but not in the molecular layer or white matter. Belongs to the
myelin proteolipid protein family.
Q810U3 Neurofascin, (RGTTVQLECR) Nfasc Single-pass type I membrane protein. Cell adhesion, ankyrin-binding
protein which may be involved in neurite extension, axonal guidance,
synaptogenesis, myelination and neuron-glial cell interactions
P04925 Major prion protein, (VVEQMCVTQYQK,
VVEQMCVTQYQKESQAYYDGR)
Prnp Cellular prion protein.
Q80U89 MKIAA0034 protein (clathrin, heavy polypeptide (HC)),
(YIQAACKTGQIKEVER, IHGCEEPATHNALAK)
Cltc Coated pits.
Q01853 Valosin containing protein, transitional endoplasmic
reticulum ATPase, (FGMTPSKGVLFYGPPGCGRK)
Vcp Necessary for the fragmentation of Golgi stacks during mitosis and for their
reassembly after mitosis
doi:10.1371/journal.pone.0004446.t001
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2’400 rpm at 4uC, supernatant was loaded onto 12% SDS-
polyacrylamide gels. Proteins were transferred to nitrocellulose
membranes (Schleicher & Schuell, Germany) by wet blotting, and
first exposed to mouse monoclonal anti-PrP antibody POM-1
[15], 1:10’000 or mouse monoclonal anti-myc antibody 4A6
(1:1000, Upstate, USA ), then to peroxidase-labeled rabbit anti-
mouse antiserum (1:10000; Zymed, CA, USA) and developed
using the ECL detection system (Pierce, USA). Antibody
incubations were performed in 1% Top Block (FLUKA,
Switzerland) in PBS-Tween for 1 hour at room temperature or
overnight at 4uC. The same protocol was applied to generate
Western blots shown in Fig. 4 D–F using anti-M6-7 antibody
(kindly provided by C. Lagenaur) diluted 1:5000, anti-CNPase
antibody (Abcam, Cambridge, UK) diluted 1:500 and anti-
Neurofascin 155 antidody (Chemicon) diluted 1:3000.
Preparation of DRMs
Brain homogenates were extracted for 1 hour on ice in 1%
Triton X-100/25 mM MES/5 mM DTT/2 mM EDTA at
pH 7.0 [16] and protease inhibitors. Extracts (500 mg protein/
ml buffer) were mixed with 60% Optiprep
TM (Nycomed,
Denmark) to reach a final concentration of 40% and overlaid in
a SW40 centrifugation tube (Beckman, CA, USA) with a step
gradient of 30 and 5% Optiprep
TM in MES-buffer. After
centrifugation at 35’000 rpm (12 hrs), 9 fractions were collected
starting from the top. The raft fraction was obtained from the
interphase 5–30% Optiprep
TM. Mouse monoclonal anti-PrP
antibodies (POM-1) and mouse monoclonal anti-flotillin 2 (BD
Transduction, USA) were used to characterize the Optiprep
TM
fractions by Western blot.
Histopathology and Immunohistochemistry
Organs were fixed in 4% formaldehyde in PBS (pH 7.5) and
paraffin-embedded. Two mm brain sections were stained with
hematoxylin-eosin (HE). Immunohistochemistry was performed
for glial fibrillary acidic protein (activated astrocytes) using a
GFAP monoclonal antibody (DAKO, Carpinteria, CA, USA).
PrP
Sc aggregates were detected on paraffin sections using
monoclonal antibody SAF-84. For histological analyses anatomic
brain regions were selected according to standard strain-typing
protocols (Bruce, 1991, Fraser, 1968). Spongiosis was evaluated on
a scale of 0–5 (not detectable, mild, moderate, severe, and status
spongiosus). Gliosis and PrP immunoreactivity were scored on a
four-degree scale (undetectable, mild, moderate, severe). Histo-
logical analyses were performed by investigators blinded to animal
identification.
Histoblot analysis
Cryosections were transferred to a nitrocellulose membrane and
digested for 4 h with 20 mg/ml of proteinase K at 37uC. Blocking
of the sections was done in 5% TopBlock, incubation with primary
(POM1: 1:10’000, 4A6: 1:1000) and secondary antibodies (Dako
D0486, AP goat anti mouse, 1:1000) were done in 1% TopBlock,
respectively. The blots were incubated in BCIP/NBT in B3 buffer
(100 mM Tris, 100 mM NaCl, 100 mM MgCl2, pH 9.5 plus
tablets and levamisole) for 45–60 min.
Scrapie cell assay in endpoint format (SCEPA)
Prion-susceptible neuroblastoma cells (subclone N2aPK1) were
exposed to 300 ml brain homogenates in 96-well plates for 3 d.
Cells were subsequently split three times 1:3 every 2 days, and
three times 1:10 every 3 days. After they reached confluence, we
filtered 25,000 cells from each well onto the membrane of an
ELISPOT plate, treated them with PK (0.5 mg/ml for 90 min at
37uC), denatured, and detected individual infected (PrP
Sc-positive)
cells by immunocytochemistry using alkaline phosphatase-conju-
gated POM1 mouse anti-PrP and an alkaline phosphatase–
conjugated substrate kit (Bio-Rad). We performed serial tenfold
dilutions in cell culture medium containing healthy mouse brain
homogenate. Scrapie-susceptible PK1 cells were then exposed to
dilutions of experimental samples ranging from 10
24 to 10
29, the
same for RML, or to a 10
24 dilution of healthy mouse brain
homogenate. Samples were quantified in endpoint format, by
counting positive wells according to established methods.
Immunoprecipitations
Brains were homogenized in 0.5% CHAPS and protease
inhibitors (Complete; Roche, Switzerland) as described above.
Mouse monoclonal anti-myc 4A6 antibody was cross linked to
Dynabeads M-280 Sheep anti-Mouse IgG (Dynal, Norway) as
recommended by the manufacturer. Four mg of total protein from
5% brain homogenates were diluted to a volume of 1.5 ml of 0.5%
CHAPS/NP-40. To precipitate the PrPmyc complex, 40 mlo f
resuspended beads were added and incubated with rotational
mixing for 2 hours at 4uC and for 15 min at room temperature.
Beads were washed twice in PBS/0.5%CHAPS/NP-40 and twice
in PBS/1% CHAPS/NP-40 at 4uC. To elute the complex, beads
were incubated for 2 h at 4uC and another 10 min at room
temperature with the synthetic specific peptide (c-myc: H-
EQKLISEEDL-NH2, Roche Diagnostics, Basel, Switzerland)
and the scrambled nonspecific peptide (cym: H-IELQKELDES-
NH2, jct, Berlin, Germany) respectively. Peptides were added in
10-fold molar excess compared to the 4A6 antibody, in a final
volume of 380 ml of 1% CHAPS, 1% NP-40.
Tryptic in-gel digestion
Silver stained bands from 12% SDS PAGE were destained and
incubated for 1–3 h in 100 mM ammonium bicarbonate
(NH4HCO3, pH 8.0, Sigma) in 50% MeOH at 37uC. The
proteins were reduced in 2 mM tris(carboxyethyl)phosphine
(TCEPNHCl, Pierce, USA) in 100 mM ammonium bicarbonate
at 37uC for 40 min and alkylated with 20 mM iodoacetamide
(Fluka, Switzerland) for 30 min at room temperature in the dark.
Gel pieces were rinsed twice in 100 mM ammonium bicarbonate,
dehydrated in acetonitrile for 10 min, dried under vacuum for
10 min and reswell in 200–400 ng of sequence-grade modified
trypsin solution (Promega, Madison, WI, USA) for 15 min at RT.
Gel pieces were covered with sufficient amount of 100 mM
ammonium bicarbonate buffer containing 2 mM CaCl2 and
incubated overnight at 37uC. Samples were sonicated for 5 min
and supernatant was pooled with an additional peptide extraction
round with 50% acetonitrile/1% formic acid for 20 min at RT.
Samples were dried under vacuum and kept at 220uC whenever
they were not used immediately.
ICAT labeling and sample processing
The IP eluate was precipitated by ethanol precipitation and the
pellet was dissolved in 100 ml of cICAT labeling buffer (50 mM
Tris, pH 8.3; 8 M Urea; 5 mM EDTA; 0.125% SDS and 0.05%
RapiGest). The cICAT labeling procedures was performed as
described previously [54,55,56]. The control sample was labeled
with the light, the specific elution sample with heavy cICAT label
(Applied Biosystems, Foster City, CA, USA). Digestion with
trypsin (Promega, Madison, WI, USA) was performed at 37uC
over night and ICAT-labeled peptides were subsequently purified
according to the manufacturer’s instructions. ZipTip columns
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of the affinity-purified fraction.
Capillary chromatography and mass spectrometric
analysis
Cleaned samples were resuspended in equilibration buffer (3%
acetonitrile/0.1 formic acid in MilliQ-water) and loaded onto a
microcapillary column constructed by slurry packing 8 cm of
reversed-phase (RP) material (Magic C18, 5 mm, 200 A ˚, Michrom
BioResources, Auburn, CA, USA) into a 75 mm fused-silica
capillary (BGB Analytik AG, Bo ¨ckten, Switzerland). Mass
spectrometric analyses were performed on an LTQ-FT
TM
(Thermo Scientific, Bremen, Germany) systems directly coupled
to a nanoLC
TM HPLC system (eksigent, Dublin, CA, USA) at a
flow rate of 200 nl/min. Peptides were eluted with an acetonitrile
gradient from 3 to 45% in approximately 55 min and data-
dependent acquisition of tandem mass spectra was continuously
repeated during the course of the analysis. Each high accuracy MS
full scan was followed by four MS/MS scans of the four most
intense peaks. High mass accuracy data was search with Mascot
Integra (Matrix Science, UK) using the UniProt mouse protein
data base (ftp.ebi.ac.uk/pub/databases/SPproteomes/fasta/
proteomes/59.M_musculus.fasta.gz), allowing for two missed
trypsin cleavage sites and precursor- and fragment ion tolerances
of 5 ppm and 0.8 Da, respectively. Peptides from ICAT samples
were identified by searching MS/MS spectra against the same
mouse protein database using Sequest [24].
PeptidePhrophet was used to assess the validity of peptide
assignments. Proteins were filtered using ProteinProphet with a
computed overall probability of $0.95 for a protein being present
in the sample. Only peptide pairs that had a mass difference of
9.0301 Da were included. Both peptide contained cysteins and
belonged to a protein that was identified with an Xcorr value$1.5.
Averages and standard deviations were calculated for each protein
expression value when multiple peptide measurements were
available. We only considered peptides with double and multiple
charges, and manually evaluated the expression values by
inspecting the areas of integration that the software had chosen
and by adjusting them as needed. To calculate protein ratio
between different pull down samples, XPRESS [56] was used.
Prion inoculations
8–12 weeks old mice were inoculated intracerebrally (ic) or
intraperitoneally (ip) with 3610
6 infectious units (IU) or 10610
6
IU, respectively, of Rocky Mountain Laboratory strain (RML,
passage 5.0) brain homogenate, prepared as described [57].
Beginning 50 days after inoculation, mice were examined daily for
neurological dysfunction and sacrificed on the day of onset of
terminal clinical signs of scrapie. For transmission experiments,
mice were inoculated ic with up 30 ml of 10% sonicated brain
homogenate. Mice were monitored clinically every other day in
order to ascertain the onset of clinical signs and the course of the
disease. Clinical signs exacerbated over time and included
progressive akinesia, priapism (males), hunchback, and stiff tail.
Mice were sacrificed on the day of onset of terminal clinical signs
of scrapie, defined as the time point at which they became unable
to drink and/or eat.
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